259 related articles for article (PubMed ID: 27496134)
1. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Song M; Kim SH; Yoon SK
Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
4. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Saito M; Ishigame T; Tsuta K; Kumamoto K; Imai T; Kohno T
Carcinogenesis; 2014 Nov; 35(11):2452-6. PubMed ID: 25064355
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance profiles of mutations in the RET kinase domain.
Liu X; Shen T; Mooers BHM; Hilberg F; Wu J
Br J Pharmacol; 2018 Sep; 175(17):3504-3515. PubMed ID: 29908090
[TBL] [Abstract][Full Text] [Related]
6. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
8. Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Song M
J Med Chem; 2015 May; 58(9):3672-81. PubMed ID: 25625428
[TBL] [Abstract][Full Text] [Related]
9. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
10. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
11. KIF5B-RET fusions in lung adenocarcinoma.
Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
[TBL] [Abstract][Full Text] [Related]
12. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
13. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
14. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
[TBL] [Abstract][Full Text] [Related]
16. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
17. KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.
Das TK; Cagan RL
Cell Rep; 2017 Sep; 20(10):2368-2383. PubMed ID: 28877471
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
19. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
20. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]